BioCentury
ARTICLE | Company News

Gene by Gene, Myriad Genetics diagnostic news

February 10, 2014 8:00 AM UTC

Gene by Gene and Myriad settled a July suit under which Myriad was alleging Gene by Gene infringed nine patents held or licensed by Myriad covering synthetic DNA and methods of use related to the breast cancer 1 early onset (BRCA1) and BRCA2 genes. The patents are U.S. Patent Nos. 5,709,999; 5,747,282; 5,753,441; 5,837,492; 6,033,857; 5,654,155; 5,750,400; 6,951,721 and 7,250,497. Under the terms of the settlement, Gene by Gene stopped marketing in North America genetic tests that include BRCA1 and BRCA2 analysis as a standalone test or in conjunction with gene panels. Gene by Gene can still market its whole genome and exome products and services, which include the BRCA genes, as well as its products that test variants for BRCA1 and BRCA2. The settlement is valid through Feb. 12, 2016. ...